Bock F, König Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C
Augenklinik mit Poliklinik, Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Deutschland.
Ophthalmologe. 2007 Apr;104(4):336-44. doi: 10.1007/s00347-007-1512-2.
Recent years have seen tremendous progress in our understanding of the mechanisms of neovascular diseases of the eye. Antiangiogenic treatment options are now widely used in the management of age-related maculopathy (AMD) and diabetic retinopathy. The aim of this article is to highlight some novel methods of local antiangiogenic treatment of the cornea and conjunctiva and in the anterior chamber of the eye.
The study took the form of a literature review (PUBMED) and a review of the authors' own data.
Initial experience with novel inhibitors of angiogenesis, especially bevacizumab, used locally on cornea and conjunctiva is promising. Intracameral injections of VEGF inhibitors can be used to ameliorate neovascular glaucoma.
Novel antiangiogenic drugs are available for topical use in the anterior segment of the eye (as off-label use) and will improve the management of neovascular diseases affecting cornea and conjunctiva and in the anterior chamber of the eye.
近年来，我们对眼部新生血管疾病机制的理解取得了巨大进展。抗血管生成治疗方案目前广泛应用于年龄相关性黄斑病变（AMD）和糖尿病视网膜病变的治疗。本文旨在强调角膜、结膜及眼前房局部抗血管生成治疗的一些新方法。
本研究采用文献综述（PUBMED）及作者自身数据回顾的形式。
新型血管生成抑制剂，尤其是贝伐单抗，在角膜和结膜局部应用的初步经验很有前景。前房内注射血管内皮生长因子（VEGF）抑制剂可用于改善新生血管性青光眼。
新型抗血管生成药物可用于眼前节局部（作为超说明书用药），并将改善影响角膜、结膜及眼前房的新生血管疾病的治疗。
